While enhanced IFNγ production by T cells has also been reported in IFN-refractory CML patients treated with imatinib [45], a more recent study showed distinct immunological status of patients treated with imatinib and IFN [46]. Here, IFNG is linked to chronic myelogenous leukemia, BCR-ABL1 positive.